Skip to main content
Explore URMC

menu

Endometrial Cancer: Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

Research Question:
Is lenvatinib in combination with pembrolizumab superior to treatment of physician's choice? Does it improve overall survival? What is the safety and tolerability treatment with lenvatinib in combination with pembrolizumab versus treatment of physician's choice?

Basic Study Information

Purpose:
If you decide to participate in this study, you will be assigned by chance to get either lenvatinib plus pembrolizumab or doxorubicin or paclitaxel. You will know what treatment you will be assigned to receive.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03517449?term=MK-3475-775%2FE7080-G000-309&rank=1
Study Reference #: IGYE18025

Lead Researcher (Principal Investigator)

Lead Researcher: Richard Moore

Study Contact Information

Study Coordinator: Laura Mitchell
Phone: (585) 275-7763
Email: Laura_Mitchell@URMC.Rochester.edu

Additional Study Details

Return to Search